{"preliminary_commentary":{"by_channel":{"x_thread":5,"youtube":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05489211\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["datopotamab deruxtecan"],["datopotamab deruxtecan","capecitabine"],["datopotamab deruxtecan","5-fluorouracil"]],"indication":"advanced/metastatic solid tumors","name":"TROPION-PanTumor03","nct_id":"NCT05489211","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tropion-pantumor03-nct05489211. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Dato-DXd will be evaluated as monotherapy","label":"Substudy-1A","type":"EXPERIMENTAL"},{"description":"Dato-DXd in combination with capecitabine will be evaluated","label":"Substudy-2A","type":"EXPERIMENTAL"},{"description":"Dato-DXd in combination with 5-FU will be evaluated","label":"Substudy-2B","type":"EXPERIMENTAL"},{"description":"Dato-DXd will be evaluated as monotherapy","label":"Substudy-3A","type":"EXPERIMENTAL"},{"description":"Dato-DXd will be evaluated in combination with prednisone/prednisolone","label":"Substudy-3C","type":"EXPERIMENTAL"},{"description":"Dato-DXd will be evaluated as monotherapy","label":"Substudy-4A","type":"EXPERIMENTAL"},{"description":"Dato-DXd in combination with carboplatin + bevacizumab followed by Dato-DXd + bevacizumab will be evaluated","label":"Substudy-4C","type":"EXPERIMENTAL"},{"description":"Dato-DXd will be evaluated as monotherapy","label":"Substudy-5A","type":"EXPERIMENTAL"},{"description":"Dato-DXd in combination with volrustomig (MEDI5752) will be evaluated","label":"Substudy-6A","type":"EXPERIMENTAL"},{"description":"Data-DXd in combination with rilvegostomig (AZD2936) will be evaluated","label":"Substudy-6B","type":"EXPERIMENTAL"},{"description":"Dato-DXd will be evaluated as monotherapy","label":"Substudy-6C","type":"EXPERIMENTAL"},{"description":"Dato-DXd in combination with carboplatin or cisplatin will be evaluated","label":"Substudy-6D","type":"EXPERIMENTAL"},{"description":"Dato-DXd in combination with rilvegostomig (AZD2936) will be evaluated","label":"Substudy-6E","type":"EXPERIMENTAL"},{"description":"Dato-DXd will be evaluated as monotherapy","label":"Substudy-7A","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2027-10-01","type":"ESTIMATED"},"conditions":["Endometrial Cancer","Gastric Cancer","Metastatic Castration-resistant Prostate Cancer","Ovarian Cancer","Colorectal Cancer","Urothelial Cancer","Biliary Tract Cancer"],"enrollment":{"count":454,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Datopotamab deruxtecan (Dato-DXd)","otherNames":["DS-1062a"],"type":"DRUG"},{"name":"Capecitabine","otherNames":["Xeloda"],"type":"DRUG"},{"name":"5-Fluorouracil","otherNames":["Adrucil"],"type":"DRUG"},{"name":"Volrustomig","otherNames":["MEDI5752"],"type":"DRUG"},{"name":"Carboplatin","otherNames":["Paraplatin"],"type":"DRUG"},{"name":"Bevacizumab","otherNames":["Avastin"],"type":"DRUG"},{"name":"Rilvegostomig","otherNames":["AZD2936"],"type":"DRUG"},{"name":"Prednisone/ prednisolone","otherNames":["Prednisolone"],"type":"DRUG"},{"name":"Cisplatin","otherNames":["Platinol"],"type":"DRUG"}],"last_update":"2026-09-23","lead_sponsor":"AstraZeneca","official_title":"A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-10-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective response rate (ORR)","timeFrame":"From baseline to progressive disease or death (approximately 1 year)"},{"measure":"The number of subjects with adverse events/serious adverse events","timeFrame":"Throughout the treatment and the safety follow-up period 28 [+ 7] days after the discontinuation of all study interventions, except durvalumab, nivolumab, and bevacizumab for which it will be 90 [+ 7] days (approximately 1 year)"},{"measure":"PSA50 response (Substudy 3 only)","timeFrame":"From baseline to PSA response evaluated according to the PCWG3 criteria (approximately 1 year)"},{"measure":"Progression free survival (PFS) response (Substudy 4C only)","timeFrame":"From baseline to progressive disease or death (approximately 1 year)"}],"references":[],"start_date":{"date":"2022-09-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","url":"https://clinicaltrials.gov/study/NCT05489211"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tropion-pantumor03-nct05489211"}